![Steffen Walter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Steffen Walter
Directeur des opérations chez
IMMATICS N.V.
Fortune : 115 100 $ au 31/05/2026
Profil
Steffen Walter is the founder of Immatics US, Inc., founded in 2015, holding the title of Chief Scientific Officer since 2015.
Dr. Walter currently holds the position of Chief Operations Officer at Immatics Biotechnologies GmbH since 2023, with the job starting in 2005 and ongoing.
Dr. Walter also holds the position of Chief Operations Officer at Immatics NV since 2023, with the job starting in 2020 and ongoing.
Dr. Walter completed a doctorate degree at Eberhard Karls Universität Tübingen.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMATICS N.V. 0,01% | 18/03/2026 | 10 000 ( 0,01% ) | 115 100 $ | 31/05/2026 |
Postes actifs de Steffen Walter
| Sociétés | Poste | Début |
|---|---|---|
| IMMATICS N.V. | Directeur des opérations | 21/03/2023 |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Fondateur | 01/01/2015 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Directeur des opérations | 21/03/2023 |
Formation de Steffen Walter
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
19
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
Eberhard Karls Universität Tübingen
 Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Health Technology |
Immatics NV
 Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
